Evidence map›Paper›PMID 40114262›Full record

ArticleArthritis research & therapy2025

Course of uveitis in children with juvenile idiopathic arthritis (JIA): Five years follow-up data from a prospective multicenter Inception Cohort of Newly diagnosed patients with JIA (ICON-JIA) study.

Karoline Baquet-Walscheid, Kirsten Minden, Martina Niewerth, Frank Dressler, Ivan Foeldvari, Dirk Foell, Johannes-Peter Haas, Gerd Horneff, Anton Hospach, Tilmann Kallinich and 6 more

Abstract readMulticenter Study
In one paragraph

Article in Arthritis research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Karoline Baquet-WalscheidDepartment of Ophthalmology at St. Franziskus Hospital, Muenster, Germany.
Kirsten MindenDeutsches Rheumaforschungszentrum Berlin, Berlin, Germany.
Martina NiewerthDeutsches Rheumaforschungszentrum Berlin, Berlin, Germany.
Frank DresslerDepartment of Pediatrics, Hannover Medical School, Hannover, Germany.
Ivan FoeldvariHamburg Centre for Paediatric and Adolescent Rheumatology, Schön Klinik Hamburg Eilbek, Hamburg, Germany.
Dirk FoellDepartment of Pediatric Rheumatology and Immunology, University Hospital Muenster, Muenster, Germany.
Johannes-Peter HaasGerman Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany.
Gerd HorneffCentre for Paediatric Rheumatology, Department of Paediatrics, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany.
Anton HospachCentre of Paediatric Rheumatology, Olga Hospital, Stuttgart, Germany.
Tilmann KallinichDepartment of Paediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Jasmin Kümmerle-DeschnerAutoinflammation Reference Center Tübingen (Arct), Division of Paediatric Rheumatology, Department of Paediatrics, University Hospital Tübingen, Tübingen, Germany.
Kirsten MönkemöllerDepartment of Pediatric and Adolescent Medicine, Kliniken Der Stadt Köln gGmbH, Cologne, Germany.
Christoph TappeinerUniversity of Duisburg-Essen, Essen, Germany.
Daniel WindschallPediatric Rheumatology, St. Josef-Stift, Sendenhorst, Germany.
Jens Klotsche *Deutsches Rheumaforschungszentrum Berlin, Berlin, Germany.
Arnd Heiligenhaus *Department of Ophthalmology at St. Franziskus Hospital, Muenster, Germany. arnd.heiligenhaus@uveitis-zentrum.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundJuvenile idiopathic arthritis-associated uveitis (JIAU) typically takes a chronic course, frequently leading to ocular complications and often requiring long-term treatment. The present study assesses the 5-years outcome of JIAU by analyzing data from a prospective study initiated in 2010.

methodsData from 75 patients with onset of uveitis after study enrollment, and with a documentation at 5-years follow-up (5yFU) were available for analysis of uveitis characteristics, frequency and predictors of "inactivity on medication " (defined as inactive uveitis for ≥ 6 months) and "inactivity off medication " (defined as inactive uveitis for ≥ 6 months off medication).

resultsAt the 5yFU, visual acuity remained good in the majority of eyes (LogMAR < 0.1 in 65.5%; mean LogMAR 0.11 ± 0.31), ocular surgery was required in only 5% of patients, although complications occurred in 46.7% of patients until the 5yFU. Uveitis was inactive in 85.3% of patients, with 77.3% still receiving disease-modifying antirheumatic drugs (DMARDs). Until 5yFU, 82.7% of patients experienced ≥ one episode of "inactivity on medication " (30.7% once, 37.3% twice, 14.7% three or more times), and 17.3% ≥ one episode of "inactivity off medication ", respectively. Both "inactivity on medication " as well as "inactivity off medication " were associated with lower JIA disease activity (cJADAS10; ESR), and with an increased quality of life.

conclusionsDespite intensified DMARD treatment, almost half of the children experience JIAU-related ocular complications after 5 years of disease; however, visual acuity mostly remains good. Uveitis inactivity can be achieved frequently, but is often limited in duration. Lower JIA activity appears to correlate with uveitis inactivity on and off medication.

Indexed as

Arthritis, JuvenileUveitisAdolescentAntirheumatic AgentsChildChild, PreschoolCohort StudiesFemaleFollow-Up StudiesHumansMaleProspective StudiesVisual AcuityAntirheumatic AgentsBiological therapyJuvenile idiopathic arthritisPrognosisUveitis

Identifiers

PMID40114262
PMCPMC11924706

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.